We understand Novo is looking to expand its sales force considerably, on the order of 40%. Perhaps they're planning to put more manpower behind Levemir, Novo's recently approved long-acting insulin that will compete with Lantus. Perhaps other things are in the works? We'll look forward to watching this unfold...
« In-store clinics at major pharmacy chains may boost sales | Main | Friday stream of consciousness on ranbaxy-lantus-apidra-symlin-pumps »
Comments
The comments to this entry are closed.
Recent Posts
- Taking our online relationships offline
- CVS Caremark’s MinuteClinic to start treating diabetes
- Sotomayor Becomes First Justice with Type 1 Diabetes
- The accuracy of blood glucose monitoring: no need for alarm
- A Great Day For Diabetes - Results from DCCT/EDIC
- Attention Type 1s - JDRF launches Clinical Trials Connection service
- Congratulations TuDiabetes!
- More menu labeling controversy
- Judge Sotomayor wins backing of Senate Committee
- Finally - a President who gets it. Invest now, save later!
Any word on Levemir's launch. I've heard that it's somewhat contingent upon/tied to continued Predictive trials here in the US but, as far as I can tell, NN isn't even recruiting patients yet. Thoughts?
Posted by: Courtney Rice | 10/19/2005 at 01:45 PM